Any current/future capex/capital investment/strategic investment?

The company announced a capital expenditure (CAPEX) of Rs. 70 crore, expected to be commercialized by October 2024. This CAPEX is for an add-on facility at the Dahej site, including 150 KL reactors and a separate distillation plant, aiming to support commercialization of new products in the PASC (Pharma and Agro intermediates) segment. The Rs. 70 crore investment is to capture growth opportunities and avoid delivery mismatches, expected to generate incremental revenue of Rs. 95-100 crore. The company also received environmental clearance for a greenfield project at Jolva, Dahej, with con

Future growth expectations in sales/revenue/volumes?

PTC segment: Organic volume growth of 10-15% per year historically; 2023 may see no volume growth due to sharp product price drops; topline degrowth expected in 2023; business stable with secured large MNC customers for 2024. PASC and SDA segments: Expected to drive future growth with commercialization starting August 2024; incremental revenue of Rs. 200 crores from PASC and Rs. 80-100 crores from SDA over next 3 years. Overall growth guidance: At least 70% revenue growth anticipated in FY25 driven by volume growth and new products; value erosion due to lower product pricing considered in

Future growth expectations in earnings/operating earnings/profits/EPS?

FY24 guidance: revenue expected in the range of Rs. 400-410 crore with EBITDA around 20% levels. FY25 outlook: anticipated growth of at least 70% in revenue driven by volume growth and new customer acquisitions, especially in SDA and PASC segments. From October 2024, plant is expected to operate at full capacity leading to margin expansion; realistic margin target around 25%. Incremental revenue over next 3 years: Rs. 200 crore from PASC (60%) and Rs. 80-100 crore from SDA (40%). PTC segment expected to remain stable with 10-15% organic volume growth yearly, but topline degrowth in FY2

Current/ Expected Orderbook/ Pending Orders?

For the calendar year 2024, Tatva Chintan Pharma Chem Limited has already secured business with most of its existing large MNC customers in the PTC segment, indicating a stable orderbook. Commercial orders have been received from a new potential customer after formal approvals on three different applications, with a fourth under validation, suggesting modest business in the first half and decent volumes from end of 2024. The company is fully qualified with two additional new customers for automotive applications, expecting business onset from April quarter. Approval progress with large custome

Tatva Chintan Pharma Chem LtdQ3 FY24Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,743P/E: 80.1Market Cap: ₹4.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

PTC segment: Organic volume growth of 10-15% per year historically; 2023 may see no volume growth due to sharp product price drops; topline degrowth expected in 2023; business stable with secured large MNC customers for 2024.
PASC and SDA segments: Expected to drive future growth with commercialization starting August 2024; incremental revenue of Rs. 200 crores from PASC and Rs. 80-100 crores from SDA over next 3 years.
Overall growth guidance: At least 70% revenue growth anticipated in FY25 driven by volume growth and new products; value erosion due to lower product pricing considered in forecasts.
Capacity Utilization: Full utilization expected from July-August 2024; new CAPEX of about Rs. 70 crores underway to expand capacity.
Longer-term: Growth supported by sustained export demand (~70% of revenue from exports); SDA segment demand to benefit post-2027 with BS-7 emission norms implementation.

Margin guidance

Category 3

FY24 guidance: revenue expected in the range of Rs. 400-410 crore with EBITDA around 20% levels.
FY25 outlook: anticipated growth of at least 70% in revenue driven by volume growth and new customer acquisitions, especially in SDA and PASC segments.
From October 2024, plant is expected to operate at full capacity leading to margin expansion; realistic margin target around 25%.
Incremental revenue over next 3 years: Rs. 200 crore from PASC (60%) and Rs. 80-100 crore from SDA (40%).
PTC segment expected to remain stable with 10-15% organic volume growth yearly, but topline degrowth in FY24 due to price erosion.
New CAPEX Rs. 70 crore planned to scale up production capacity, with full utilization anticipated from July-August 2024, boosting EBITDA.
BS-7 SDA opportunity expected to materialize in FY26, supporting long-term growth.
Overall, margin and profit growth expected post full capacity utilization and commercialization of new products.

See what Tatva Chintan Pharma Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The provided transcript and document pages do not mention any current or planned fundraising activities through debt or equity. Key points related to funding are: - The company is undertaking a CAPEX of Rs. 70 crores for expansion, funded from internal or existing resources (no mention of external fundraising). - Earlier CAPEX of about Rs. 150-250 crores was done during the IPO, but no new equity or debt raising is indicated. - The company is confident about meeting future growth with existing capacity expansions without mentioning fresh fundraising. - No specific references to raising funds through debt or equity in the near future were made during the call or presentation. Hence, no current or future fundraising through debt or equity is disclosed in this material.

Order book

For the calendar year 2024, Tatva Chintan Pharma Chem Limited has already secured business with most of its existing large MNC customers in the PTC segment, indicating a stable orderbook.
Commercial orders have been received from a new potential customer after formal approvals on three different applications, with a fourth under validation, suggesting modest business in the first half and decent volumes from end of 2024.
The company is fully qualified with two additional new customers for automotive applications, expecting business onset from April quarter.
Approval progress with large customers in the electrolyte salts and PASC segments also indicates forthcoming order inflow, with commercial supplies expected to start by mid to late 2024 and 2025.
The business pipeline includes 6 new product commercializations scheduled from August 2024 onwards, which is expected to lead to capacity utilization and revenue growth.

See what Tatva Chintan Pharma Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company announced a capital expenditure (CAPEX) of Rs. 70 crore, expected to be commercialized by October 2024.
This CAPEX is for an add-on facility at the Dahej site, including 150 KL reactors and a separate distillation plant, aiming to support commercialization of new products in the PASC (Pharma and Agro intermediates) segment.
The Rs. 70 crore investment is to capture growth opportunities and avoid delivery mismatches, expected to generate incremental revenue of Rs. 95-100 crore.
The company also received environmental clearance for a greenfield project at Jolva, Dahej, with construction planned to start in 2025.
Further CAPEX was about Rs. 250 crore from IPO proceeds, leading to asset turn improvements and capacity expansion across PTC, SDA, and PASC segments.
Additional continuous flow reactors are being added at the lab and pilot scales as part of ongoing development projects.

Track Tatva Chintan Pharma Chem Ltd — get its next earnings analysis in your feed

How does Tatva Chintan Pharma Chem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisTatva Chintan Pharma Chem Ltd

Rev 3Mar 3

See where Tatva Chintan Pharma Chem Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?

Compare Tatva Chintan Pharma Chem Ltd against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Tatva Chintan Pharma Chem Ltd Q3 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season